HER2 Positive Breast Cancers
1 clinical trials · Condition
◉ Watch HER2 Positive Breast Cancers
| Record | Firm | Date |
|---|---|---|
| A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer (NCT01983501) | Seagen Inc. | 2014-02-28 |
Track HER2 Positive Breast Cancers automatically
Every clearance here is in the API, with alerts when new ones post.